-+ 0.00%
-+ 0.00%
-+ 0.00%

Headway Capital joins syndicate backing Samfara acquisition of Chr. Olesen Synthesis

PUBT·10/02/2026 17:25:41
Listen to the news
Headway Capital joins syndicate backing Samfara acquisition of Chr. Olesen Synthesis
  • Headway Capital Partners backed Samfara’s acquisition of Chr. Olesen Synthesis as a lead investor in a syndicate.
  • Chr. Olesen Synthesis is a Danish developer and manufacturer of controlled-substance active pharmaceutical ingredients and advanced intermediates.
  • Operations sit near Copenhagen, with a cGMP-certified plant in commercial production since 2015.
  • Key products include buprenorphine and lisdexamfetamine, supplying pharmaceutical customers across Europe, North America, and the Middle East.
  • Financial terms were not disclosed; Samfara plans investment to expand capabilities, customers, products, and new markets.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Headway Capital Partners LLP published the original content used to generate this news brief on October 02, 2026, and is solely responsible for the information contained therein.